{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02442817",
      "OrgStudyIdInfo": {
        "OrgStudyId": "LING-1"
      },
      "Organization": {
        "OrgFullName": "University of Nevada, Reno",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Linagliptin and Mesenchymal Stem Cells: A Pilot Study",
      "OfficialTitle": "Linagliptin and Mesenchymal Stem Cells: A Pilot Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2, 2015",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 2, 2018",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2, 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "May 8, 2015",
      "StudyFirstSubmitQCDate": "May 8, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 13, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 5, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 9, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Nevada, Reno",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Augusta University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.",
      "DetailedDescription": "This study is a 13-week, open-label study of 8 participants with schizophrenia and minimal thought disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment. The principal outcome measures will be the concentrations of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in blood."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Schizophrenia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "DPP-4 Inhibitor",
          "Linagliptin",
          "SDF1-α"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 4"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Basic Science",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Linagliptin patients with schizophrenia",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Linagliptin"
              ]
            }
          },
          {
            "ArmGroupLabel": "Linagliptin control group",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Linagliptin"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Linagliptin",
            "InterventionDescription": "12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Linagliptin control group",
                "Linagliptin patients with schizophrenia"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Tradjenta"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "SDF1-α (stromal cell-derived factor alpha) Concentration",
            "PrimaryOutcomeTimeFrame": "Blood will be collected on the first week and then biweekly for 12 weeks."
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "DPP-4 (Dipeptidyl peptidase-4) Activity",
            "SecondaryOutcomeTimeFrame": "Blood will be collected on the first week and then biweekly for 12 weeks."
          },
          {
            "SecondaryOutcomeMeasure": "Monocyte State",
            "SecondaryOutcomeDescription": "Flow cytometry will be used to examine the state of monocytes to look for cells recently arrived from the bone marrow and to examine the polarization (pro-inflammatory vs. anti-inflammatory) of the monocytes",
            "SecondaryOutcomeTimeFrame": "Blood will be collected on the first week and then biweekly for 12 weeks."
          },
          {
            "SecondaryOutcomeMeasure": "Absolute/Differential leukocyte count",
            "SecondaryOutcomeDescription": "Flow cytometry will be used.",
            "SecondaryOutcomeTimeFrame": "Blood will be collected on the first week and then biweekly for 12 weeks."
          },
          {
            "SecondaryOutcomeMeasure": "CD271+ cells",
            "SecondaryOutcomeDescription": "Flow cytometry will be used to detect CD271+ cells.",
            "SecondaryOutcomeTimeFrame": "Blood will be collected on the first week and then biweekly for 12 weeks."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMeets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia.\nConsidered clinically stable, and on the same dose of antipsychotic for two weeks.\nA score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item.\nNot taking any medications for diabetes, or any anti-inflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine.\nAge 18-45 years.\nCan be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays.\n\nExclusion Criteria:\n\nDoes not meet DSM criteria for substance abuse or dependence.\nNo serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "45 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Brian Kirkpatrick, MD",
            "OverallOfficialAffiliation": "University of Nevada School of Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Nevada School of Medicine",
            "LocationCity": "Reno",
            "LocationState": "Nevada",
            "LocationZip": "89503",
            "LocationCountry": "United States"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000012559",
            "ConditionMeshTerm": "Schizophrenia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000019967",
            "ConditionAncestorTerm": "Schizophrenia Spectrum and Other Psychotic Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M14528",
            "ConditionBrowseLeafName": "Schizophrenia",
            "ConditionBrowseLeafAsFound": "Schizophrenia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20991",
            "ConditionBrowseLeafName": "Schizophrenia Spectrum and Other Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000069476",
            "InterventionMeshTerm": "Linagliptin"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000007004",
            "InterventionAncestorTerm": "Hypoglycemic Agents"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000054795",
            "InterventionAncestorTerm": "Incretins"
          },
          {
            "InterventionAncestorId": "D000006728",
            "InterventionAncestorTerm": "Hormones"
          },
          {
            "InterventionAncestorId": "D000006730",
            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
          },
          {
            "InterventionAncestorId": "D000054873",
            "InterventionAncestorTerm": "Dipeptidyl-Peptidase IV Inhibitors"
          },
          {
            "InterventionAncestorId": "D000011480",
            "InterventionAncestorTerm": "Protease Inhibitors"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M445",
            "InterventionBrowseLeafName": "Linagliptin",
            "InterventionBrowseLeafAsFound": "SOC",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M27110",
            "InterventionBrowseLeafName": "Dipeptidyl-Peptidase IV Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M16056",
            "InterventionBrowseLeafName": "Antipsychotic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9206",
            "InterventionBrowseLeafName": "Hypoglycemic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M27058",
            "InterventionBrowseLeafName": "Incretins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8941",
            "InterventionBrowseLeafName": "Hormones",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M8940",
            "InterventionBrowseLeafName": "Hormone Antagonists",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18761",
            "InterventionBrowseLeafName": "HIV Protease Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M13495",
            "InterventionBrowseLeafName": "Protease Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hypo",
            "InterventionBrowseBranchName": "Hypoglycemic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "CNSDep",
            "InterventionBrowseBranchName": "Central Nervous System Depressants"
          },
          {
            "InterventionBrowseBranchAbbrev": "PsychDr",
            "InterventionBrowseBranchName": "Psychotropic Drugs"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          }
        ]
      }
    }
  }
}